Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia

CJ Helal, Z Kang, X Hou, J Pandit…

Index: Journal of Medicinal Chemistry, , vol. 54, # 13 p. 4536 - 4547

Full Text: HTML

Citation Number: 33

Abstract

... Journal of Medicinal Chemistry. ... With an interest in being able to examine the effect of a PDE10A inhibitor in a clinical setting, we sought to bring forward a number of structurally diverse chemical series that would increase the chances of finding a compound with the ...

Use of structure-based design to discover a potent, selectiv...

[Helal, Christopher J.; Kang, Zhijun; Hou, Xinjun; Pandit, Jayvardhan; Chappie, Thomas A.; Humphrey, John M.; Marr, Eric S.; Fennell, Kimberly F.; Chenard, Lois K.; Fox, Carol; Schmidt, Christopher J.; Williams, Robert D.; Chapin, Douglas S.; Siuciak, Judith; Lebel, Lorraine; Menniti, Frank; Cianfrogna, Julia; Fonseca, Kari R.; Nelson, Frederick R.; O Connor, Rebecca; MacDougall, Mary; McDowell, Laura; Liras, Spiros Journal of Medicinal Chemistry, 2011 , vol. 54, # 13 p. 4536 - 4547]

4-Quinazolinyloxy-diaryl ureas as novel BRAF V600E inhibitor...

[Bioorganic and Medicinal Chemistry Letters, , vol. 21, # 18 p. 5342 - 5346]